Oral nifedipine versus labetalol in treatment of postpartum hypertension

Oral nifedipine versus labetalol in treatment of postpartum hypertension - antihypertensive in postpartum

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00014081

Enrollment

100

Registered

2018-03-12

Start date

2018-03-09

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension O13

Interventions

Group 1: Epilat retard (nifedipine), 60 mg/day p.o (tablet), for 2 days the dose is below the maximum dose Group 2: Labipress (labetalol), 400mg/day p.o. (tablet), for 2 days

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women who have hypertension during pregnancy and persist after delivery till discharge of hospital

Exclusion criteria

Exclusion criteria: Women with history of secondary hypertension Women with eclampsia who need intensive care unit admission and indicated other drugs rather than oral nifedipine and oral labetalol Women who have any contraindication to Nifedipine or labetalol

Design outcomes

Primary

Measure	Time frame
Duration and total dose to achieving blood pressure below the critical value between 140 and 150 mmHg systoloic and 90-100 mmHg diastolic till discharge of hospital about two days	—

Secondary

Measure	Time frame
Resolution of complications Improvement of heamatological values and other investigations Side effects in both groups	—

Countries

Egypt

Contacts

Public ContactAhmed Mohamed Embaby

Lecturer of Ob&Gyn

abdelmagied.ahmed@aun.edu.eg0201096636884

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026